PCP-mAb

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NamePCP-mAb
Drug Alias NameInterveXimab-PCPInterveXin-PCPch-mAb6B (university of Arkansas/InterveXion Therapeutics)chimeric anti-phencyclidine antibody (University of Arkansas/InterveXion Therapeutics)anti-PCP monoclonal antibody (University of Arkansas/InterveXion Therapeutics)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsSubstance-Related Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity of Arkansas
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIntervexion Therapeutics LlcUniversity of Arkansas
Active IndicationsN/A
Inactive IndicationsSubstance-Related Disorders

Other Information

ATC CodeN/A
Related LinksN/A